DRUG STUDY FOR ETORICOXIB

DRUG NAME CLASSIFICATIO ACTION INDICATION CONTRAINDICATIO ADVERSE EFFECTS NURSING

N N RESPONSIBILITIE
S

Generic Name: Etoricoxib Therapeutic Selectively For the treatment Hypersensitivity to Asthenia/fatigue,  Administer
Class: NSAID inhibits isoform of rheumatoid etoricoxib & NSAIDs. dizziness, lower extremity medication
Brand Name: Arcoxia 2 of cyclo- arthritis, Patients w/ history of edema, HTN, dyspepsia, following the 14
Pharmacologic oxigenase osteoarthritis, CVA, MI, coronary heartburn, nausea, Rights of drug
Dosage/Route/ Class: enzyme (COX- ankylosing artery bypass graft. increased ALT & AST. administration.
Frequency: 120 mg/tab COX-2 selective 2), preventing spondylitis, Active peptic Thrombocytopenia,  Noted for any
OD et chronic low back hypersensitivity reactions hypersensitivity
inhibitor production of ulceration or GI
pain, acute pain including reaction.
prostaglandins bleeding. Previous
and gout. anaphylactic/anaphylactoi  Monitored vital
(PGs) from history of d reactions including signs and
arachidonic bronchospasm, acute shock; hyperkalemia, assessed for
acid. rhinitis, nasal polyps, anxiety, insomnia, orthostatic
angioneurotic edema, confusion, hallucinations, hypotension or
urticaria or allergic- depression, restlessness; signs of CNS
type reactions after dysgeusia, somnolence, depression.
taking aspirin or blurred vision, CHF,  Advised patient
NSAIDs including palpitations, angina, that he can take
COX-2 inhibitors. arrhythmia, hypertensive the medication
Severe hepatic crisis, bronchospasm,
regardless of
abdominal pain, oral
dysfunction (serum food intake.
ulcers, peptic ulcer
albumin <25 g/L or
including perforation or
Child-Pugh score bleeding (elderly),
≥10). Estimated renal vomiting, diarrhea,
CrCl <30 mL/min. hepatitis, jaundice; hepatic
Inflammatory bowel failure, angioedema,
disease. CHF (NYHA pruritus, erythema, rash,
II-IV). Established Stevens-Johnson
ischemic heart syndrome, toxic epidermal
disease, peripheral necrolysis, urticaria; fixed-
arterial &/or drug eruption, renal
cerebrovascular insufficiency including
 disease. Inadequately renal failure.
controlled HTN.
Pregnancy &
lactation. Childn &
adolescent <16 yr.

DRUG STUDY FOR MYELAX

NURSING
DRUG NAME CLASSIFICATION ACTION INDICATION CONTRAINDICATION ADVERSE EFFECTS
RESPONSIBILITIES

Generic Name: Myelax Therapeutic: Tramadol is a Symptomatic Hypersensitivity. Weakness, dizziness or  Administered
Antispasmodic centrally acting treatment of Severe myasthenia. drowsiness. medication
analgesic that muscle spasm &
Brand Name: has opioid spasticity. following the 14
Eperisone Pharmacologic: agonist Rights of drug
Central-acting properties. It administration.
Dosage/route/Frequency: muscle relaxants. binds to μ-  Assessed for
50 mg OD opiate receptors mentioned
in the CNS
contraindications
resulting in
and cautions to
inhibition of
ascending pain prevent untoward
pathways, thus complications.
altering the  Conduct thorough
perception of physical
and response to assessment to
pain. Its obtain baseline
inhibition of data.
neuronal uptake  Monitor liver and
of renal function
norepinephrine
tests to detect
and
potential adverse
enhancement of
serotonin effects.
release may  Provided comfort
also contribute measures to help
to its analgesic patient tolerate
effect. drug effects.

DRUG STUDY FOR CEFTRIAXONE

NURSING
DRUG NAME CLASSIFICATION ACTION INDICATION CONTRAINDICATION ADVERSE EFFECTS
RESPONSIBILITIES
Generic Name: Therapeutic Ceftriaxone is It is used for the Hypersensitivity to Significant: Stevens-  Administered
Ceftriaxone Classification: a 3rd treatment of the cephalosporins or Johnson syndrome, toxic medication
Antibacterial generation infections history of severe epidermal necrolysis following the 14
Brand Name: cephalosporin (respiratory, hypersensitivity to (TEN)/Lyell’s syndrome, Rights of drug
Ceftex Pharmacologic Antibacterial. It skin, soft tissue, other type of β-lactam hypersensitivity, renal and administration.
Classification: binds to 1 or UTI, ENT) Antibacterial gallbladder precipitation,  Obtained CBC,
Dosage/route/Frequency: 3 rd
Generation caused by (penicillins,
more penicillin- pancreatitis secondary to renal function
2g IV OD cephalosporin susceptible monobactams,
binding biliary obstruction, renal tests.
organisms. carbapenems).
proteins Organisms that Premature neonates lithiasis, superinfection.  Questioned
(PBPs) are generally up to a postmenstrual Blood and lymphatic history of
inhibiting the susceptible to age of 41 weeks system disorders: allergies,
final ceftriaxone (gestational age and particularly
Eosinophilia, leucopenia, cephalosporin,
transpeptidatio include S. chronological age), full-
thrombocytopenia. penicillin.
n step of pneumoniae, S. term neonates (up to
pyogenes 28 days of age) with  Assessed oral
peptidoglycan
(group A beta- hyperbilirubinemia, cavity for white
synthesis in Gastrointestinal
hemolytic jaundice, patches on
bacterial cell disorders: mucous
wall, leading to streptococci), hypoalbuminemia, or
coagulase- acidosis requiring IV Diarrhea, oral candidiasis. membranes,
bacterial cell tongue (thrush).
negative calcium treatment, or
lysis and  Monitored daily
staphylococci, calcium containing
death. Some infusions. General disorders and pattern of bowel
Enterobacter admin site activity, stool
spp, H. conditions: Diaphoresis. consistency.
influenzae, N.
gonorrhoeae, P.
mirabilis, E. coli, Injury, poisoning and
Klebsiella spp, procedural
M. catarrhalis, complications:
B. burgdorferi,
and some oral
anaerobes. Pain, induration and
tenderness at injection
site (IM).
Investigations:
Increased hepatic
 enzymes, BUN and
serum creatinine;
sonographic
abnormalities in the
gallbladder.

Nervous system
disorders:
Headache, dizziness.

Skin and subcutaneous

tissue disorders:
Rash.

Vascular disorders:
Flushing.

Potentially Fatal:

Severe haemolytic
anaemia, Clostridium
difficile-associated
diarrhoea (CDAD).

DRUG STUDY FOR KALIUM DURULE

 NURSING
DRUG NAME CLASSIFICATION ACTION INDICATION CONTRAINDICATION ADVERSE EFFECTS
RESPONSIBILITIES

Generic Name: P Therapeutic: Principal To prevent and Hypersensitivity. Renal GI:Nausea, vomiting,  Administered medication
Potassium Minerals and intracellular treat potassium insufficiency, diarrhea, abdominal following the 14 Rights of
Chloride electrolytes cation; deficit secondary hyperkalemia, untreated distension. drug administration.
essential for to diuretic or Addison's disease, Whole Body:Pain,
 Closely monitored vital
maintenance of corticosteroid stricture of the mental confusion,
Brand Name: Pharmacologic: signs.
irritability, listlessness,
Kalium Durule Minerals and intracellular therapy. Also esophagus &/or
paresthesias of  Monitored I&O ratio and
isotonicity, indicated when obstructive changes in
electrolytes extremities, muscle pattern in patients
transmission of potassium is the alimentary tract.
Dosage/route/ weakness and
nerve depleted by receiving the parenteral
Frequency: impulses, severe vomiting, heaviness of limbs,
difficulty in swallowing, drug. If oliguria occurs,
1 tab OD contraction of diarrhea; intestinal
flaccid paralysis. stop infusion promptly
cardiac, drainage, fistulas,
Urogenital:Oliguria, and notify physician.
skeletal, and or malabsorption;
anuria.  Monitored lab test results
smooth prolonged Hematologic:Hyperkal
muscles, diuresis, diabetic for serum electrolytes.
emia.
maintenance of acidosis. Effective Respiratory:Respirator  Monitored for and report
normal kidney in the treatment of y distress. signs of GI ulceration
function, and hypokalemic CV:Hypotension, (esophageal or epigastric
for enzyme alkalosis bradycardia; cardiac pain or hematemesis).
activity. Plays a (chloride, not the depression,
prominent role gluconate). arrhythmias, or arrest;
 Be alert for potassium
in both altered sensitivity to intoxication); may result
formation and digitalis from any therapeutic
correction of glycosides. ECG dosage, and the patient
imbalances in changes in may be asymptomatic.
acid–base hyperkalemia,
metabolism. ventricular fibrillation

DRUG STUDY FOR GASMOTIN

 NURSING
DRUG NAME CLASSIFICATION ACTION INDICATION CONTRAINDICATION ADVERSE EFFECTS
RESPONSIBILITIES

Generic Name: P Therapeutic: It increases the Indicated for the Hypersensitivity. Patients Diarrhea/loose stools,  Administered medication
Mosapride Citrate Gastroprokinetic release of treatment of w/ GI hemorrhage, dry mouth, malaise, following the 14 Rights of
agent acetylcholine gastrointestinal mechanical obstruction or eosinophilia, drug administration.
Brand Name: and stimulates symptoms perforation. increased  Closely monitored I&O
Gasmotin Pharmacologic: GI motility. It associated with triglycerides, AST
and vital signs.
Selective 5HT₄ also has 5-HT3 functional (GOT), ALT (GPT),
antagonist dyspepsia, ALP, γ-GTP &  Assessed for symptoms
Dosage/route/ agonist of dehydration, such as
properties. chronic gastritis bilirubin; fulminant
Frequency: decreased blood pressure
(heartburn, hepatitis, hepatic
1 tab TID ac nausea, vomiting). dysfunction, jaundice, associated with
It speeds up the edema, leukopenia, tachycardia, decreased
process of gastric abdominal pain, skin turgor, and
emptying and nausea, vomiting,
decreased urine output or
prevents reflux of taste abnormality,
food into the food palpitation, dizziness, dark concentrated urine.
pipe. light-headedness,  Monitored hemoglobin,
headache. hematocrit, and serum
sodium levels for
additional signs of
dehydration.
 Instructed the patient to
drink enough fluids to
avoid dehydration.
 Instructed the patient to
only eat bland foods if
possible and stay away
from spicy, fatty, or salty
foods.